4,4'-diaponeurosporene: a yellow carotenoid pigment of Staphylococcus aureus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4,4'-diaponeurosporene : An apo carotenoid triterpenoid that is tetracosane which is substituted by methyl groups at positions 2, 6, 10, 15, 19, and 23, and contains double bonds at the 2-3 and 22-23 positions, and E-double bonds at the 4-5, 6-7, 8-9, 10-11, 12-13, 14-15, 16-17, and 18-19 positions. It is a yellow carotenoid pigment of Staphylococcus aureus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6443791 |
| CHEBI ID | 62743 |
| MeSH ID | M0240574 |
| Synonym |
|---|
| 4,4'-diaponeurosporene |
| LMPR01070132 |
| 53872-50-7 |
| all-trans-4,4'-diaponeurosporene |
| 7,8-dihydro-4,4'-diapocarotene |
| (4e,6e,8e,10e,12e,14e,16e,18e)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaene |
| CHEBI:62743 |
| c4d , |
| 2,4,6,8,10,12,14,16,18,22-tetracosadecaene, 2,6,10,15,19,23-hexamethyl-, (all-e)- |
| Q27132139 |
| (4e,6e,8e,10e,12e,14e,16e,18e)-2,6,10,15,19,23-hexamethyl-2,4,6,8,10,12,14,16,18,22-tetracosadecaene |
| DTXSID301113843 |
| Class | Description |
|---|---|
| apo carotenoid triterpenoid | A triterpenoid compound arising from loss of part of the carotene skeleton. |
| triterpene | A C30 terpene. |
| polyene | An olefin that contains more than one carbon-carbon double bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| 4,4'-diapolycopenedioate biosynthesis | 3 | 16 |
| staphyloxanthin biosynthesis | 4 | 21 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||